Sees Q3 adjusted EBITDA C$9.6M-C$10.6M. “This quarter’s guidance showcases the strength and momentum of High Tide (HITI) like never before. We expect to deliver record revenue and powerful sequential Adjusted EBITDA growth. These results have been fueled by a projected 7.4% increase in same-store sales during the quarter, which was our fastest growth rate in two years,” said Raj Grover, Founder and Chief Executive Officer of High Tide. “These results, anticipated to be well above analyst expectations, highlight how underappreciated our core Canadian business remains. With our entry into Germany, through the recently announced acquisition of a majority stake in Remexian Pharma GmbH, we’re no longer just a Canadian success story-we’re building the next global cannabis powerhouse.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HITI:
- High Tide Expands into German Medical Cannabis Market with Remexian Acquisition
- High Tide to acquire 51% of Remexian Pharma GmbH for EUR 27.2M
- High Tide Announces Strategic Updates and Financing Flexibility
- High Tide Expands with New Canna Cabana Store in Alberta
- High Tide Reaches Loyalty Milestones and Prepares for Future Growth